The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 3, 2006, Pages 213-216

  Cetin, Hasan ^a,c   Yalaz, Mehmet ^b   Akisu, Mete ^b   Karapinar, Deniz Y ^b   Kavakli, Kaan ^b   Kultursay, Nilgun ^b  

^a SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c NONE   (Turkey)

Author keywords

Massive pulmonary hemorrhage; Preterm infant; Recombinant activated factor VII

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRIN DEGRADATION PRODUCT; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TEICOPLANIN;

ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; LUNG HEMORRHAGE; LUNG VENTILATION; MALE; MORBIDITY; OXYGENATION; PARTIAL THROMBOPLASTIN TIME; PREMATURITY; PRIORITY JOURNAL; PROTHROMBIN TIME; RESPIRATORY DISTRESS SYNDROME; SEPSIS;

DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR VIIA; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; LUNG DISEASES; MALE; RECOMBINANT PROTEINS; SEPSIS;

EID: 33645529357     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000220245.20036.2d     Document Type: Article

References (14)

1. Miller MJ, Fanarof AA, Martin RJ. Respiratory disorders in preterm and term infants. In: Fanarof, AA, Martin, RJ, editors. Neonatal perinatal medicine: diseases of the fetus and infant. 7th ed. vol. 2. St Louis, MO: Mosby; 2002. pp. 1025-1049.
2. Hansen T, Corbet A. Pulmonary physiology of the newborn. In: Taeusch HW, Ballard RA, editors. Avery's diseases of the newborn, 7th ed. Philadelphia, PA: WB Saunders; 1998, pp. 562-575.
3. Finlay ER, Subhedar NV. Pulmonary hemorrhage in preterm infants. Eur J Pediatr 2000; 159:870-871.
4. Maksic H, Heljic S, Maksic S, Jonuzi F. Pulmonary complications during mechanical ventilation in the neonatal period. Med Arhiv 2000; 54:271-272.
5. Streif W, Andersen RB, Paes B, Berry L, XU L, Andrew M, Chan AK. Influence of activated factor VII concentrates on thrombin generation in full term and preterm neonates. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S133-S134.
6. Veldman A, Fischer D, Voigt B, Beyer PA, Schlosser R, Allendorf A, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002; 28:1635-1637.
7. Wong WY, Huang WC, Miller R, McGinty K, Whisnanti JK. Clinical efficacy and recovery levels of recombinant FVIIa (Novoseven®) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Hemophilia 2000; 6:50-54.
8. Tancabelic J, Haun SE. Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus Type 7. Pediatr Blood Cancer 2004; 43:170-176.
9. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 1 (Suppl):S61-S65.
10. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114:114-120.
11. Martinez J, Cid AR, de la Rubia J, Gimeno R. Treatment of intra-abdominal bleeding with recombinant activated factor VII in a patient with disseminated intravascular coagulation secondary to septic shock. Blood Coagul Fibrinolysis 2005; 16:297-299.
12. Moscardo F, Perez F, de la Rubia J, Balerdi B, Lorenzo JI, Senent ML, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 114:174-176.
13. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2:899-909.
14. Millar CG, Stringer MD, Sugarman I, Richards M. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11:171-174.